Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Daniil Stroyakovskii"'
Autor:
Aditya Bardia, Peter Schmid, Nadia Harbeck, Mothaffar F Rimawi, Sara A Hurvitz, Sherene Loi, Shigehira Saji, Kyung Hae Jung, Gustavo Werutsky, Daniil Stroyakovskii, Vanesa López-Valverde, David Tesarowski, Chenglin Ye, Michael Davis, Tanja Badovinac Crnjevic, Pablo Diego Perez-Moreno, Charles E Geyer
Publikováno v:
Cancer Research. 82:OT2-11
BACKGROUND ETs that target ER activity and/or estrogen synthesis are the mainstay of ER+ BC treatment. Despite best management, up to 20% of pts with ER+/HER2- eBC develop resistance (in some cases due to the acquisition of tumor mutations in ESR1 th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5de221b6bbfe76af4d838d6dc90c25da
https://doi.org/10.1158/1538-7445.sabcs21-ot2-11-09
https://doi.org/10.1158/1538-7445.sabcs21-ot2-11-09
Autor:
Whitney P. Kirschbrown, Daniil Stroyakovskii, Christian Jackisch, Christian Schem, Tanja Badovinac Crnjevic, Antoinette R. Tan, Zbigniew Nowecki, Michelino De Laurentiis, Kyung Hae Jung, Mahesh Shivhare, André Mattar, Seock-Ah Im, Sarah Heeson, Eleonora Restuccia, Ramon Colomer, Jean-Yves Pierga
Publikováno v:
Cancer Research. 80:PD4-07
Background: Intravenous pertuzumab (P IV) + trastuzumab (H IV) + chemotherapy (CT) improves outcomes in patients (pts) with HER2-positive breast cancer, compared with H + CT.A new subcutaneous (SC) formulation, for the first time combining two monocl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b378256832d66d15933e5cd17777ed3f
https://doi.org/10.1158/1538-7445.sabcs19-pd4-07
https://doi.org/10.1158/1538-7445.sabcs19-pd4-07
Autor:
Christian Jackisch, Seock-Ah Im, Michelino De Laurentiis, Jean-Yves Pierga, Mahesh Shivhare, Ramon Colomer, Kyung Hae Jung, Tanja Badovinac Crnjevic, Alexandra Hogea, Daniil Stroyakovskii, Sarah Heeson, Antoinette R. Tan, Zbigniew Nowecki, André Mattar, Whitney P. Kirschbrown, Christian Schem, Eleonora Restuccia
Publikováno v:
The Lancet. Oncology. 22(1)
Summary Background A subcutaneous formulation of pertuzumab and trastuzumab with recombinant human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab, trastuzumab, and hyaluronidase-zzxf) was approved by the US Food and Drug A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99e575a2761394ec388f6b5a6dee91bf
https://pubmed.ncbi.nlm.nih.gov/33539750
https://pubmed.ncbi.nlm.nih.gov/33539750
Autor:
M. De Laurentiis, Daniil Stroyakovskii, Antoinette R. Tan, Zbigniew Nowecki, Eleonora Restuccia, Christian Jackisch, Christian Schem, J-Y. Pierga, Kyung Hwa Jung, André Mattar, Mahesh Shivhare, Sarah Heeson, T. Badovinac Crnjevic, R. Colomer, A. Alexandrou, S-A. Im, Christian Aguila
Publikováno v:
Annals of Oncology. 32:S40-S41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2829d67d9bbdf8f69eb27e6b4335ba09
https://doi.org/10.1016/j.annonc.2021.03.060
https://doi.org/10.1016/j.annonc.2021.03.060
Autor:
Andriy Rusyn, Vladimir Moiseyenko, Valeriy Baryash, Dmitry Komov, Dmytro Boliukh, Daniil Stroyakovskii, Sang Joon Lee, Edvard Zhavrid, Justin Stebbing, Joanna Pikiel, Giorgi Dzagnidze, Yauheni Valerievich Baranau, Sung Young Lee, Alexandru Eniu, Rubi K. Li, Gabriela Morar-Bolba, Alexey Manikhas, Francisco J. Esteva
Publikováno v:
The Lancet. Oncology. 18(7)
Summary Background CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breast cancer. Methods In this random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4307529393a7a2271c09b1be158cfbe8
https://pubmed.ncbi.nlm.nih.gov/29129095
https://pubmed.ncbi.nlm.nih.gov/29129095